Navigation Links
UChicago and Evelo Therapeutics Partner to Advance Microbiome-based Cancer Immunotherapy

CAMBRIDGE, Mass., Nov. 9, 2015 /PRNewswire/ -- A partnership between Evelo Therapeutics and the University of Chicago will advance an immunotherapy that employs certain gut microbes to boost the immune system's attack on cancer cells and improve the effectiveness of anti-cancer drugs.

A new study, published in the Nov. 5 issue of Science, University of Chicago researcher Thomas Gajewski showed that certain species of bacteria added to the digestive tracts of mice increased the ability of the animals' immune systems to attack tumor cells and, when combined with anti-PD-L1, an investigational anti-cancer antibody in the drug class known as checkpoint inhibitors, nearly eradicated tumors.

An exclusive agreement between the University of Chicago and Evelo provides the company with the option to acquire worldwide rights to the microbiome-based immunotherapy developed by Gajewski, who is a professor of medicine and pathology at UChicago.

The immunotherapy adds to Evelo's research into the power of the microbiome to disrupt and fight cancer. Flagship Ventures, a leader in life sciences innovation and venture creation, last week launched Evelo with an initial funding commitment of $35 million.

"Our partnership with Professor Gajewski and UChicago advances Evelo's platform to leverage the ability of bacteria to activate the immune system to drive tumors into remission," said Simba Gill, Ph.D., chief executive officer for Evelo. "We are privileged to be working with Professor Gajewski to translate his pre-clinical work to the clinical setting and bring these therapies to patients as quickly as possible."

Evelo's platform, Oncobiotic™ therapeutics, is a new modality in cancer therapy based on the cancer microbiome. Products developed through this platform are designed to disrupt the tumor microenvironment.

"Through our partnership with Evelo Therapeutics, we can harness the company's expertise to commercialize components of the microbiome and provide Dr. Gajewski with the opportunity to take his research from the bench to the bedside," said Thelma Tennant, assistant director at UChicagoTech, the Center for Technology Development and Ventures, the organization which negotiated the agreement for UChicago.

Many important steps remain to understand how this technology will translate in the setting of cancer treatment in humans. Evelo, Gajewski and UChicago will work together to bring this technology to the patient setting as quickly as possible, while continuing to explore the mechanisms of the microbiome in cancer.

"I am pleased to work with the team at Evelo to further develop this therapeutic approach and take it to clinical trials. With Evelo we can drive this program forward quickly for the ultimate benefit of patients," Gajewski said.

Gajewski will also serve on the Scientific Advisory Board at Evelo. In this capacity, Gajewski will work closely with Evelo as it commercializes microbiome-based cancer immunotherapy and develops new Oncobiotic™ therapies based on a deep understanding of the interaction between the microbiome, the immune system and cancer.

About Thomas Gajewski
Thomas Gajewski, M.D., Ph.D. is leader of the immunology program at the University of Chicago Cancer Center, and director of Melanoma Oncology. He has been involved in numerous NIH grant review panels, has been on editorial boards for the Journal of Immunology, Cancer Research, and Clinical Cancer Research, has served on the program committees for AACR and ASCO, and is past president of the Society for Immunotherapy of Cancer. Dr. Gajewski has received the Burroughs Wellcome Fund Clinical Scientist Award for Translational research, and been inducted into the American Society for Clinical Investigation and the Henry Kunkel Society. Dr. Gajewski has a joint appointment in pathology and hematology/oncology at the University of Chicago.

About Evelo Therapeutics
Evelo Therapeutics is dedicated to transforming cancer therapy through a deep understanding of the cancer microbiome. Evelo is discovering and developing Oncobiotic™ therapies, novel treatments designed to attack cancer by disrupting the microbial environment that supports tumors and protects them from the body's immune system. Evelo's platform disrupts the tumor microenvironment at the metabolic and stromal levels and provides next-generation, microbiome-based immunotherapeutics. Founded at Flagship VentureLabs, Evelo is the first microbiome company focused on cancer. For more information, please visit

About the University of Chicago
As one of the world's premier research universities, the University of Chicago empowers students and scholars through its commitment to free and open inquiry. Across numerous departments and disciplines, as well as more than 140 institutes and centers, the UChicago community advances ideas and innovations that enrich human life. UChicago's faculty are some of the top in the world. The University of Chicago has 89 Nobel Prize winners, including 6 current faculty, and receives more than $450 million in sponsored research awards each year. Please visit:

The agreement between Evelo and UChicago was facilitated by UChicagoTech, the University's Center for Technology Development & Ventures.

SOURCE Flagship Ventures
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Cachexia Pipeline Review and Therapeutic Development for H2 2015 Available in Market Research Report
2. Rosa & Co. Presented a Poster at the 2015 Roche Pharma Research and Early Development (pRED) Symposium
3. FDA grants Fast Track designation for development of CAM2038, long-acting buprenorphine injections to treat opioid addiction
4. Glucose Monitoring Market 21 Company Profiles, 2020 Development Trends and Analysis Report
5. Global Hospital Infection Therapeutics Market 2015-2019 - Development of Multidrug Resistant Variants Is a Key Market Driver
6. Allergan Enters Into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment
7. Regulus Expands Development of RG-101 through Clinical Trial Collaboration with GSK
8. Debiotech and Fresenius Medical Care Announce Exclusive Partnership for New Home Dialysis Product Development
9. Axovant Announces Expansion of Dementia Drug Development Pipeline and Reports Financial Results for the Second Fiscal Quarter and Six Months Ended September 30, 2015
10. Training Program is Key to Developing and Maintaining Engineering Talent, Benchmarking Study Shows
11. Emerging Opportunities in the US Enteric Diseases Diagnostic Testing Market 2016 - Profiles Key Suppliers and Potential Market Entrants Developing Innovative Technologies and Products
Post Your Comments:
(Date:10/8/2019)... ... 08, 2019 , ... A free, interactive event highlighting innovations and ideas helping ... event, featuring thought leaders, innovators and health experts, will display innovations that could help ... to 5:30 p.m. CT on October 19 at the Coppertank Event Center in Austin, ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today ... Mandalay Bay Resort & Casino, Las Vegas on Oct. 15 – 19, 2019. ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... breast cancer and provide safer, convenient options for patients who require treatment. The ... System. Contrast enhanced mammography is used to detect tumors in dense breasts that ...
Breaking Medicine Technology:
(Date:10/8/2019)... Columbia (PRWEB) , ... October 08, 2019 , ... What ... current and future state of aging and wellness in the nation? That question will ... on Active Aging Conference, Leadership Summit and Expo. The event will take place October ...
(Date:10/8/2019)... ... October 08, 2019 , ... Drs. Joel Rosenlicht and ... missing teeth restore their smiles with long-lasting dental implants . Placing over ... i-CAT® 3D Cone Beam CT imaging, X-Guide™ software and Yomi® robotic-assisted technology to ...
(Date:10/8/2019)... ... October 08, 2019 , ... METAvivor Research and Support Inc., a non-profit organization ... its Stage IV Stampede campaign. The campaign will commence with two days of action ... an advocacy boot camp, a march, a Die-In (hosted by partner MET-UP), and visits ...
(Date:10/8/2019)... ... 08, 2019 , ... On November 9, 2019, husband and wife dental team, Dr.’s Michael and ... . 2019 marks the ninth consecutive year that Mansouri Family Dental Care & Associates ... , This event has always had a great turnout, serving over 300 people in a ...
(Date:10/8/2019)... WASHINGTON (PRWEB) , ... October 08, 2019 , ... Shady Grove Fertility (SGF) , ... has announced more than 82% of participants who use their own eggs take home a ... baby. , The refund guarantee program was developed 27 years ago by SGF ...
Breaking Medicine News(10 mins):